Clinical Trial Update: A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase II study investigating toripalimab plus RC48-ADC with radiotherapy for bladder preservation in HER2-positive muscle-invasive bladder cancer; status is not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Urothelial Carcinoma

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Tongji Hospital | Conditions: Muscle-invasive Bladder Urothelial Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING